Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Elimusertib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Cervical cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Lymphadenopathy; Mouth neoplasm; Oropharyngeal cancer; Salivary gland cancer; Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker
- 17 Feb 2024 Planned End Date changed from 5 Feb 2025 to 27 Nov 2024.
- 17 Feb 2024 Planned primary completion date changed from 1 Apr 2026 to 27 Nov 2024.
- 07 Feb 2024 Planned End Date changed from 1 Apr 2026 to 5 Feb 2025.